Patient advocacy groups in Canada with ties to pharma are big boosters for government coverage

As the interplay between the pharmaceutical industry and patient advocacy groups undergoes stepped-up scrutiny, a new analysis finds a large majority of Canadian groups that submitted comments about pending government coverage for medicines also held conflicts with drug makers.